Effects of Digital Therapeutic in Whole Process Management of Lung Cancer

Sun Yat-sen University

Status and phase

Enrolling

Phase 3

Conditions

Application of Digital Therapeutic in Lung Cancer Whole Process Management

Treatments

Other: UHealth digital therapeutic

Study type

Interventional

Funder types

Other

Identifiers

NCT06230445

A2023-002

Details and patient eligibility

About

This trial will randomize patients into two groups, the treatment group will use the digital therapeutic application named 'UHealth' for the whole process management and the control group will use regular follow-up. The trial aims to look into the difference between quality of life, anxiety/depression index, emergency treatment times, hospital admission rate, treatment compliance, OS, DFS and follow-up cost.

Enrollment

900 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with histologically or cytologically confirmed lung cancer;
Patients have received surgery, neoadjuvant therapy, adjuvant therapy, radiotherapy or other chemotherapy, such as cytotoxic chemotherapy, targeted therapy and immunotherapy;
ECOG (Performance status) 0-1;
Patients aged > 18 years and < 70 years;
The patients themselves or their family members are familiar with mobile and internet;

Exclusion criteria

Patients have disease progression in the screening period;
Patients with symptomatic brain metastasis;
Patients with dementia, schizophrenia or other psychological diseases that may affect the cognitive behavior;
Other medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information;
Women who are pregnant or in the period of breastfeeding.